Press release
HER2+ Gastric Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sa
HER2+ Gastric Cancer Pipeline Insights 2024
HER2+ Gastric Cancer Overview:
Gastric cancer ranks as the sixth most common cancer globally and the third leading cause of cancer-related deaths. Early-stage gastric cancer is often asymptomatic, with most symptoms appearing only in advanced stages. Common late-stage symptoms include unexplained weight loss, stomach pain, loss of appetite, difficulty swallowing, fatigue, nausea, vomiting, heartburn, and indigestion. Gastric cancer develops due to genetic mutations in stomach cells, causing abnormal cell growth and tumor formation.
A subset of gastric cancers is HER2-positive, characterized by overexpression of the HER2 protein, which promotes tumor growth. HER2, a member of the EGFR family, is encoded by a gene located on chromosome 17 (17q21). HER2-positive cancers can benefit from targeted therapies that inhibit the HER2 protein, though only a minority of patients achieve a cure through surgical resection, with many experiencing recurrence.
The HER2 protein, also known as ErbB2/Neu, is a 185 kDa transmembrane glycoprotein with three key components: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. Advances in HER2-targeted treatments provide a promising approach for managing HER2-positive gastric cancers.
Request for a HER2+ Gastric Cancer pipeline insights 2024 report @ https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"HER2+ Gastric Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the HER2+ Gastric Cancer Therapeutics Market.
Key Takeaways from the HER2+ Gastric Cancer Pipeline Report
DelveInsight's HER2+ Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2+ Gastric Cancer treatment.
In July 2024, Merck & Co. announced that the Phase 3 KEYNOTE-811 trial achieved its dual primary endpoint of overall survival (OS). The study evaluated Keytruda in combination with trastuzumab and chemotherapy containing fluoropyrimidine and platinum for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
In April 2024, ENHERTU® (fam-trastuzumab deruxtecan-nxki) has received approval in the US as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors who have undergone prior treatment.
Key HER2+ Gastric Cancer companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, and others are evaluating new drugs for HER2+ Gastric Cancer to improve the treatment landscape.
Promising HER2+ Gastric Cancer pipeline therapies in various stages of development include SHR-A1811, Cinrebafusp alfa, BI-1607, and others.
Request for detailed information on HER2+ gastric cancer pipeline insights report @ https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
HER2+ Gastric Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the HER2+ Gastric Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2+ Gastric Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the HER2+ Gastric Cancer market.
HER2 Positive Gastric Cancer Emerging Drugs
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Cinrebafusp alfa: Pieris Pharmaceuticals
BI-1607: BioInvent International
HER2+ Gastric Cancer Companies
Approximately 20 or more key companies are actively developing therapies for HER2-positive gastric cancer. Among these, Jiangsu HengRui Medicine Co., Ltd. has drug candidates in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
HER2+ Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
HER2+ Gastric Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging HER2+ Gastric Cancer Therapies and Key Companies: HER2+ Gastric Cancer Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
HER2+ Gastric Cancer Pipeline Therapeutic Assessment
• HER2+ Gastric Cancer Assessment by Product Type
• HER2+ Gastric Cancer By Stage
• HER2+ Gastric Cancer Assessment by Route of Administration
• HER2+ Gastric Cancer Assessment by Molecule Type
Download HER2+ Gastric Cancer Sample report to know in detail about the HER2+ Gastric Cancer treatment market @ HER2+ Gastric Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. HER2+ Gastric Cancer Current Treatment Patterns
4. HER2+ Gastric Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. HER2+ Gastric Cancer Late-Stage Products (Phase-III)
7. HER2+ Gastric Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. HER2+ Gastric Cancer Discontinued Products
13. HER2+ Gastric Cancer Product Profiles
14. HER2+ Gastric Cancer Key Companies
15. HER2+ Gastric Cancer Key Products
16. Dormant and Discontinued Products
17. HER2+ Gastric Cancer Unmet Needs
18. HER2+ Gastric Cancer Future Perspectives
19. HER2+ Gastric Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the HER2+ Gastric Cancer Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sa here
News-ID: 3804926 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
